Glenmark Pharmaceuticals Ltd. (Glenmark), a research-led, global pharmaceuticals company, proudly announced the launch of the next phase of ‘India First Heart First’ campaign.
Atraverse Medical, a medical device company spearheading cutting edge left-heart access innovation, has reported the US FDA approval of its HOTWIRE radiofrequency (RF) guidewire, a novel device that empowers zero trade left-heart access while...
Centogene NV, the crucial life science partner for data-driven answers in rare and neurological illnesses, has announced the discovery of a new small molecule alongside Evotec SE. The novel chemical has the potential to help individuals with type...
Chiesi Group, a pharmaceutical firm, declared the marking of a memorandum of understanding with Karolinska Institutet, a medical university. The understanding cements a responsibility between the two associations to team up on joint endeavors...
Mankind Pharma, a pharmaceutical firm, posted more than 65% in its final quarter profit, assisting areas of strength by request in its chronic drugs segment. The organization has also sanctioned a fundraising of up to 75 billion rupees or an...
Boehringer Ingelheim, a pharmaceutical firm, added that the domestic medication controller has endorsed a medication for Generalised Pustular Psoriasis (GPP) flares in grown-ups. The organization has secured an endorsement from the Central Drugs...
MediciNova, Inc., a biopharmaceutical firm, said that it has obtained a Notice of Allowance from the United States Patent and Trademark Office for a pending patent application for MN-166 (ibudilast) for the treatment of chlorine-induced acute...
Fortis Hospital Bannerghatta Road, recently achieved yet another significant clinical milestone with the successful completion of complex Robotic Kidney Transplant Surgeries for end-stage kidney disease
Hutchmed (China), a biopharmaceutical firm, declares that it has started a registrational stage III clinical preliminary of HMPL-306 in patients with changed isocitrate dehydrogenase (IDH) 1 or 2 backslid/refractory intense myeloid leukemia (AML)...
Instylla, Inc., a clinical-stage firm focused on creating fluid embolics for peripheral vascular embolotherapy, declared the completion of patient enlistment in the continuous Instylla HES Hypervascular Tumour Pivotal...
, CDSCO.jpg)
